[go: up one dir, main page]

AR037496A1 - Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables - Google Patents

Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables

Info

Publication number
AR037496A1
AR037496A1 ARP020102823A ARP020102823A AR037496A1 AR 037496 A1 AR037496 A1 AR 037496A1 AR P020102823 A ARP020102823 A AR P020102823A AR P020102823 A ARP020102823 A AR P020102823A AR 037496 A1 AR037496 A1 AR 037496A1
Authority
AR
Argentina
Prior art keywords
fluorophenyl
physiologically acceptable
chroman
pyridylmethyl
aminomethyl
Prior art date
Application number
ARP020102823A
Other languages
English (en)
Inventor
Seyfried Christoph Dr
Hermann Russ
Bartoszyk Gerd Dr
Weber Frank Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR037496A1 publication Critical patent/AR037496A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso del (R/S)-(ñ)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cromano o una sal fisiológicamente aceptable del mismo y/o el uso del (S)-(+)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cromano o una sal fisiológicamente aceptable del mismo para la fabricación de un medicamento para el tratamiento de los trastornos extrapiramidales del movimiento y/o de los efectos adversos en trastornos extrapiramidales del movimiento. Asimismo se describen las composiciones farmacéuticas que como principios activos contienen: (i) (R/S)-(ñ)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cromano o una sal fisiológicamente aceptable del mismo y (ii) al menos una droga anti-Parkinsoniana, en combinación con uno o más excipientes farmacéuticamente aceptables. También se describen las composiciones farmacéuticas que como principios activos contienen: (i) (S)-(+)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cromano o una sal fisiológicamente aceptable del mismo y (ii) al menos una droga anti-Parkinsoniana, en combinación con uno o más excipientes farmacéuticamente aceptables.
ARP020102823A 2001-07-26 2002-07-26 Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables AR037496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26

Publications (1)

Publication Number Publication Date
AR037496A1 true AR037496A1 (es) 2004-11-17

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102823A AR037496A1 (es) 2001-07-26 2002-07-26 Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables

Country Status (24)

Country Link
US (1) US7872030B2 (es)
EP (1) EP1408964B1 (es)
JP (1) JP2004538289A (es)
KR (1) KR20040029325A (es)
CN (1) CN1292749C (es)
AR (1) AR037496A1 (es)
AT (1) ATE352302T1 (es)
AU (1) AU2002355170B2 (es)
BR (1) BR0211358A (es)
CA (1) CA2455621C (es)
CY (1) CY1107616T1 (es)
DE (1) DE60217870T2 (es)
DK (1) DK1408964T3 (es)
ES (1) ES2280602T3 (es)
HK (1) HK1068793A1 (es)
HU (1) HUP0402092A3 (es)
MX (1) MXPA04000775A (es)
MY (1) MY134059A (es)
PE (1) PE20030277A1 (es)
PL (1) PL208258B1 (es)
PT (1) PT1408964E (es)
RU (1) RU2297833C2 (es)
SI (1) SI1408964T1 (es)
WO (1) WO2003009835A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907382E (pt) 2005-07-26 2015-09-25 Bial Portela & Ca Sa Derivados de nitrocatecol como inibidores de comt
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
EP3178933B1 (en) 2009-09-11 2019-11-13 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
BR112014014341A2 (pt) 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ,エス.アー. パーキンソン病を遅延させるための医薬

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
EP0630238A4 (en) 1992-03-11 1995-05-24 Interneuron Pharma REDUCTION OF FLUCTUATIONS AFTER MEALS OF PLASMIC CONCENTRATIONS OF LARGE NEUTRAL ACIDS.
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
ATE210657T1 (de) 1994-10-14 2001-12-15 Merck Patent Gmbh Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
AU2981099A (en) 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
JP2002513001A (ja) 1998-04-29 2002-05-08 アメリカン・ホーム・プロダクツ・コーポレイション 抗精神病性のインドリル誘導体
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
HUP0402092A3 (en) 2010-06-28
CA2455621C (en) 2010-11-16
PE20030277A1 (es) 2003-03-25
EP1408964A2 (en) 2004-04-21
RU2004105844A (ru) 2005-05-10
CN1535150A (zh) 2004-10-06
DK1408964T3 (da) 2007-05-21
PL208258B1 (pl) 2011-04-29
KR20040029325A (ko) 2004-04-06
CA2455621A1 (en) 2003-02-06
PT1408964E (pt) 2007-05-31
CY1107616T1 (el) 2013-03-13
US20040171645A1 (en) 2004-09-02
JP2004538289A (ja) 2004-12-24
MXPA04000775A (es) 2004-04-20
EP1408964B1 (en) 2007-01-24
RU2297833C2 (ru) 2007-04-27
ES2280602T3 (es) 2007-09-16
WO2003009835A2 (en) 2003-02-06
MY134059A (en) 2007-11-30
SI1408964T1 (sl) 2007-06-30
AU2002355170B2 (en) 2007-06-07
PL367291A1 (en) 2005-02-21
BR0211358A (pt) 2004-09-21
CN1292749C (zh) 2007-01-03
HUP0402092A2 (hu) 2005-02-28
ATE352302T1 (de) 2007-02-15
DE60217870T2 (de) 2007-11-15
US7872030B2 (en) 2011-01-18
HK1068793A1 (en) 2005-07-29
DE60217870D1 (de) 2007-03-15
WO2003009835A3 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
PE20242299A1 (es) Composiciones agonistas de gip/glp1
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066315A (es) Derivados de la piridazina y su uso como agentes terapéuticos
PA8548701A1 (es) Azaindoles
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DK1906916T3 (da) Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
CL2022000889A1 (es) Inhibidores del factor d del complemento para administración oral
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
UY39727A (es) Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5)
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
ECSP003551A (es) Complejo farmaceutico

Legal Events

Date Code Title Description
FB Suspension of granting procedure